Various cookies are used on our website: We use technically necessary cookies for the purpose of enabling functions such as login or a shopping cart. We use optional cookies for marketing and optimization purposes, in particular to place relevant and interesting ads for you on Meta's platforms (Facebook, Instagram). You can refuse optional cookies. More information on data collection and processing can be found in our privacy policy.
Craig M. Misch, DDS, MDS, is a clinical associate professor at the University of Florida, the University of Alabama, the University of Pennsylvania, and the University of Michigan in the departments of periodontics and prosthodontics. He serves as editor-in-chief of The International Journal of Oral Implantology and on the editorial boards of the Journal of Oral Implantology and the International Journal of Periodontics & Restorative Dentistry. Dr Misch has been a featured speaker for numerous organizations and published more than 50 articles and 20 textbook chapters. He maintains a private practice as a dual specialist in Sarasota, Florida.
1st Edition 2024 Book Hardcover; 21.6 x 27.9 cm, 384 pages, 1800 illus Language: English Category: Implantology Stock No.: 19471 ISBN 978-1-64724-125-4 QP USA
The 14th International Symposium on Periodontics and Restorative Dentistry (ISPRD)
9. Jun 2022 — 12. Jun 2022Boston Marriott Copley Place, Boston, MA, United States of America
Speakers: Tara Aghaloo, Edward P. Allen, Evanthia Anadioti, Wael Att, Vinay Bhide, Markus B. Blatz, Scotty Bolding, Lorenzo Breschi, Jeff Brucia, Daniel Buser, Luigi Canullo, Daniele Cardaropoli, Stephen J. Chu, Donald Clem, Christian Coachman, Lyndon F. Cooper, Daniel Cullum, Lee Culp, José Carlos Martins da Rosa, Sergio De Paoli, Marco Degidi, Nicholas Dello Russo, Serge Dibart, Joseph P. Fiorellini, Mauro Fradeani, Stuart J. Froum, David Garber, Maria L. Geisinger, William Giannobile, Luca Gobbato, Ueli Grunder, Galip Gürel, Chad Gwaltney, Christoph Hämmerle, Robert A. Horowitz, Marc Hürzeler, David Kim, Gregg Kinzer, Christopher Köttgen, Ina Köttgen, Purnima S. Kumar, Burton Langer, Lydia Legg, Pascal Magne, Kenneth A. Malament, Jay Malmquist, George Mandelaris, Pamela K. McClain, Michael K. McGuire, Mauro Merli, Konrad H. Meyenberg, Craig M. Misch, Julie A. Mitchell, Marc L. Nevins, Myron Nevins, Michael G. Newman, Miguel A. Ortiz, Jacinthe M. Paquette, Stefano Parma-Benfenati, Michael A. Pikos, Giulio Rasperini, Pamela S. Ray, Christopher R. Richardson, Isabella Rocchietta, Marisa Roncati, Marco Ronda, Paul S. Rosen, Maria Emanuel Ryan, Irena Sailer, Maurice Salama, David M. Sarver, Takeshi Sasaki, Todd Scheyer, Massimo Simion, Michael Sonick, Sergio Spinato, Dennis P. Tarnow, Lorenzo Tavelli, Douglas A. Terry, Tiziano Testori, Carlo Tinti, Istvan Urban, Hom-Lay Wang, Robert Winter, Giovanni Zucchelli
Quintessence Publishing Co., Inc. USA
This author's journal articles
International Journal of Oral Implantology, 3/2023
PubMed ID (PMID): 37767613Pages 171-172, Language: EnglishMisch, Craig M.
Purpose: The aim of this retrospective study was to determine if penicillin allergy and/or clindamycin therapy may contribute to a higher incidence of postsurgical infections after bone augmentation.
Materials and Methods: This retrospective study analyzed patients between 2014 and 2019 who received bone augmentation procedures (socket grafting [SG]; ridge augmentation [RA]) prior to placement of dental implants. All the grafting procedures were performed under preoperative and postoperative oral antibiotic coverage with either amoxicillin or clindamycin for patients who reported penicillin allergy. Infections associated with the bone augmentation procedures were recorded.
Results: In this study, 1,814 patients received 2,961 bone augmentation procedures (2,530 SG, 431 RA). In the 2,530 SG procedures, 270 (10.7%) were associated with a penicillin allergy. Infections occurred in 91 of the 2,530 SG sites (3.6%). However, the infection rate was 10.7% (29 SG sites) for clindamycin and only 2.7% (62 SG sites) for amoxicillin (P < .02). In the 431 RA procedures, 71 (16.5%) were associated with a penicillin allergy. Overall infections occurred in 31 of the 431 sites (7.2%). However, the infection rate was 22.5% (16 RA sites) for clindamycin and only 4.2% for amoxicillin (15 RA sites; P < .01). Penicillin-allergic patients taking clindamycin demonstrated a higher risk of infection with a risk ratio of 6.9 (95% CI) and 4.5 (95% CI) compared with nonallergic patients taking amoxicillin for RA and SG, respectively.
Conclusion: Penicillin allergy and the use of clindamycin following SG and RA procedures was associated with a higher rate of infection and may be a risk factor for bone augmentation complications.
Vertical bone augmentation (VBA) procedures for dental implant placement are biologically and technically challenging. Systematic reviews and meta-analyses of studies on VBA have failed to identify clinical procedures that provide superior results for treatment of the vertical ridge deficiencies. A decision tree was developed to guide clinicians on selecting treatment options based on reported vertical bone gains (< 5 mm, 5 to 8 mm, > 8 mm). The choice of a particular augmentation technique will also depend on other factors, including the size and morphology of the defect, location, and clinician or patient preferences. Surgeons should consider the advantages and disadvantages of each option for the clinical situation and select an approach with low complications, low cost, and the highest likelihood of success.